In France, Abolis said that HealthTech Bioactives (HTBA) said it has chosen the company as a partner to develop strains to produce valuable polyphenols.
The initial phase of the partnership will focus on developing two high-value molecules with limited sourcing availability. Up to eight additional molecules will be added to the development pipeline. This strategic collaboration aims to secure production, increase capacities, and reduce manufacturing costs compared to traditional extraction methods.
The companies noted that this partnership marks an important step forward in the development of biobased production methods for high-value polyphenols.
Cyrille Pauthenier, co-founder and CEO of Abolis, said: “Abolis has a proven track record in microbial strain development for these products, and HTBA brings deep market knowledge worldwide. This partnership is a perfect match between our complementary expertise.”
More on the story.
Tags: France, HealthTech Bioactives, polyphenols
Category: Fuels
